Clinical Trial Update: Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study [NA]

View source ↗

Summary

A single-center randomized pilot study comparing valacyclovir versus valganciclovir for CMV and EBV prophylaxis in kidney transplant recipients; recruitment is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection
• Epstein-barr Virus Infection

Drugs mentioned

• VALTREX (valacyclovir hydrochloride)
• Valcyte (valganciclovir)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Kidney Transplantation, Cytomegalovirus Infections, EBV Infection | NA | Status: RECRUITING